PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug–drug interactions with clarithromycin and paroxetine
Archives of Pharmacal Research · 2024
DOI: 10.1007/s12272-024-01495-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Pharmacal Research, 2024. Verfasst von Chang-Keun Cho und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea. Hauptthemen laut MEDLINE: Venlafaxine Hydrochloride, Clarithromycin, Cytochrome P-450 CYP2D6, Drug Interactions. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 107 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder, social anxiety disorder, generalized anxiety disorder, and panic disorder. Venlafaxine is metabolized to the active metabolite desvenlafaxine mainly by CYP2D6. Genetic polymorphism of CYP2D6 and coadministration with other medications can significantly affect the pharmacokinetics and/or pharmacodynamics of venlafaxine and its active metabolite. This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was performed by comparing the predicted pharmacokinetic parameters and plasma concentration-time profiles to the observed data. Predicted plasma concentration-time profiles of venlafaxine and its active metabolite were visually similar to the observed profiles and all predicted AUC and Cmax values for respective compounds were included in the twofold error range of observed values in non-genotyped populations and different CYP2D6 genotypes. When clarithromycin or clarithromycin plus paroxetine was concomitantly administered, predicted plasma concentration-time profiles of venlafaxine properly captured the observed profiles in two different CYP2D6 genotypes and all predicted DDI ratios for AUC and Cmax were included within the acceptance range. Consequently, the present model successfully captured the pharmacokinetic alterations of venlafaxine and its active metabolite according to CYP2D6 genetic polymorphism as well as the DDIs between venlafaxine and two CYP inhibitors. The present model can be used to predict the pharmacokinetics of venlafaxine and its active metabolite considering different races, ages, coadministered drugs, and CYP2D6 activity of individuals and it can contribute to individualized pharmacotherapy of venlafaxine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
- School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea. sylee@skku.edu.
- College of Pharmacy, Dankook University, Cheonan, 31116, Republic of Korea.
- College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea.
- College of Pharmacy, Dongguk University-Seoul, Goyang, 10326, Republic of Korea. cichoi@dongguk.edu.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Cho, C. K., Kang, P., Jang, C. G., Lee, S. Y., Lee, Y. J., Bae, J. W., & Choi, C. I. (2024). PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug–drug interactions with clarithromycin and paroxetine. Archives of Pharmacal Research. https://doi.org/10.1007/s12272-024-01495-0
Vancouver
Cho CK, Kang P, Jang CG, Lee SY, Lee YJ, Bae JW, et al. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug–drug interactions with clarithromycin and paroxetine. Archives of Pharmacal Research. 2024. doi:10.1007/s12272-024-01495-0
BibTeX
@article{Cho2024,
author = {Cho, Chang-Keun and Kang, Pureum and Jang, Choon-Gon and Lee, Seok-Yong and Lee, Yun Jeong and Bae, Jung-Woo and Choi, Chang-Ik},
title = {PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug–drug interactions with clarithromycin and paroxetine},
journal = {Archives of Pharmacal Research},
year = {2024},
doi = {10.1007/s12272-024-01495-0}
}
EUVIMED